Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to determine the effects and toxicity of gemcitabine alone or gemcitabine plus enzastaurin in participants with pancreatic cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

• Diagnosis of adenocarcinoma of the pancreas.

• Pretreatment tumor specimen must be available.

• No prior chemotherapy immunotherapy, biological therapy, or hormonal therapy for pancreatic cancer, including 5-fluorouracil (5-FU) with radiation therapy.

• Prior radiation allowed.

• Ability to stop some types of anti-seizure medicines within 14 days of enrollment.

Exclusion Criteria:

• Endocrine pancreatic tumor or ampullary cancer.

• Central Nervous System (CNS) metastases.

• Inability to swallow tablets.

• 10% or greater weight loss over the 6 weeks before study entry.